Molecule Information

General Information of the Molecule (ID: Mol04365)

Name	Tumor necrosis factor receptor superfamily member 3 (LTBR) ,Homo sapiens
Synonyms	Lymphotoxin-beta receptor; Tumor necrosis factor C receptor; Tumor necrosis factor receptor 2-related protein; Tumor necrosis factor receptor type III Click to Show/Hide
Molecule Type	Protein
Gene Name	LTBR
Gene ID	4055
Sequence	MLLPWATSAPGLAWGPLVLGLFGLLAASQPQAVPPYASENQTCRDQEKEYYEPQHRICCS RCPPGTYVSAKCSRIRDTVCATCAENSYNEHWNYLTICQLCRPCDPVMGLEEIAPCTSK R KTQCRCQPGMFCAAWALECTHCELLSDCPPGTEAELKDEVGKGNNHCVPCKAGHFQNT SS PSARCQPHTRCENQGLVEAAPGTAQSDTTCKNPLEPLPPEMSGTMLMLAVLLPLAFF LLL ATVFSCIWKSHPSLCRKLGSLLKRRPQGEGPNPVAGSWEPPKAHPYFPDLVQPLLP ISGD VSPVSTGLPAAPVLEAGVPQQQSPLDLTREPQLEPGEQSQVAHGTNGIHVTGGSM TITGN IYIYNGPVLGGPPGPGDLPATPEPPYPIPEEGDPGPPGLSTPHQEDGKAWHLAE TEHCGA TPSNRGPRNQFITHD Click to Show/Hide
Function	Receptor for the heterotrimeric lymphotoxin containing LTAand LTB, and for TNFS14/LIGHT . Activates NF-kappa-Bsignaling pathway upon stimulation with lymphotoxin -LTB). Promotes apoptosis via TRAF3 and TRAF5. May play arole in the development of lymphoid organs.{ECO:0000269\|PubMed:10799510, ECO:0000269\|PubMed:24248355,ECO:0000269\|PubMed:8171323}. Click to Show/Hide
Uniprot ID	TNR3_HUMAN
Ensembl ID	ENSG0000011132111
HGNC ID	HGNC:6718
*Click to Show/Hide the Complete Species Lineage*
Kingdom: Metazoa Phylum: Chordata Class: Mammalia Order: Primates Family: Hominidae Genus: Homo Species: Homo sapiens

Type(s) of Resistant Mechanism of This Molecule

RTDM: Regulation by the Disease Microenvironment

Drug Resistance Data Categorized by Drug

Approved Drug(s)

1 drug(s) in total

Click to Show/Hide the Full List of Drugs

Bortezomib

Click to Show/Hide

Drug Resistance Data Categorized by Their Corresponding Mechanisms
Regulation by the Disease Microenvironment (RTDM)			Click to Show/Hide
Disease Class: Multiple myeloma [ICD-11: 2A83.0]				[1]
Resistant Disease	Multiple myeloma [ICD-11: 2A83.0]			Disease Info
Resistant Drug	Bortezomib			Drug Info
Molecule Alteration	Expression		Up-regulation
Experimental Note	Revealed Based on the Cell Line Data
In Vitro Model	NCI-H929 cells	Bone marrow	Homo sapiens (Human)	CVCL_1600
Experiment for Molecule Alteration	Western blot assay
Experiment for Drug Resistance	MTT assay
Mechanism Description	In particular, the dynamic interaction between BM mesenchymal stem cells (BM-MSC) and MM cells has shown great relevance. Here we showed that inhibiting both PKC and NF-kappaB signalling pathways in BM-MSC reduced cell survival in the MM cell line H929 and increased its susceptibility to the proteasome inhibitor bortezomib. PKC-mediated cell survival inhibition and bortezomib susceptibility induction were better performed by the chimeric peptide HKPS than by the classical enzastaurin inhibitor, probably due to its greatest ability to inhibit cell adhesion and its increased capability to counteract the NF-kappaB-related signalling molecules increased by the co-cultivation of BM-MSC with H929 cells. Thus, inhibiting two coupled signalling molecules in BM-MSC was more effective in blocking the supportive cues emerging from the mesenchymal stroma.

References

Ref 1	Simultaneously Targeting Two Coupled Signalling Molecules in the Mesenchymal Stem Cell Support Efficiently Sensitises the Multiple Myeloma Cell Line H929 to Bortezomib. Int J Mol Sci. 2023 May 2;24(9):8157.